Der var ingen forskel i infektionsraten blandt patienter behandlet med Enbrel og patienter, som fik placebo mod plaque psoriasis, i placebokontrollerede undersøgelser af op til 24 ugers varighed.
There were no differences in rates of infection among patients treated with Enbrel and those treated with placebo for plaque psoriasis in placebo controlled trials of up to 24 weeks duration.